Literature DB >> 10446460

cDNA and protein characterization of human MAGE-10.

D Rimoldi1, S Salvi, D Reed, P Coulie, V C Jongeneel, E De Plaen, F Brasseur, A M Rodriguez, T Boon, J C Cerottini.   

Abstract

MAGE genes are frequently expressed in several types of human malignancy and code for antigens recognized by cytotoxic T lymphocytes. We have previously described a monoclonal antibody (MAb), named 6C1, that recognizes the MAGE-1 protein and cross-reacts with a 72-kDa protein present in lysates of melanoma cells such as MZ2-MEL. To identify this protein, we have screened an expression library prepared from MZ2-MEL cells. Several clones that encoded a protein recognized by antibody 6C1 contained a sequence identical to that of MAGE-10, another member of the MAGE-A gene family. Full-length MAGE-10 cDNA clones, obtained after screening additional cDNA melanoma libraries, were found to be approximately 2.5 kb in length. In vitro translation and transient transfection experiments indicated that MAGE-10 codes for a protein of approximately 72 kDa. This product was recognized by MAb 6C1 as well as by a polyclonal serum raised against a MAGE-10 peptide, thus demonstrating its identity with MAGE-10. Analysis of MAGE-10 mRNA by RT-PCR confirmed its presence in testis and placenta but not in other normal tissues. Expression of MAGE-10 in melanoma tumors was found to parallel that of MAGE-1. Western blot analysis with the polyclonal anti-MAGE-10 antibody showed the presence of MAGE-10 in lysates of purified trophoblast cells. Immuno-cytochemistry of cultured melanoma cells indicated that MAGE-10 is a nuclear protein. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446460     DOI: 10.1002/(sici)1097-0215(19990909)82:6<901::aid-ijc21>3.0.co;2-x

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.

Authors:  Elena Grau; Silvestre Oltra; Francisco Martínez; Carmen Orellana; Adela Cañete; Jose María Fernández; Miguel Hernández-Martí; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-27       Impact factor: 4.553

2.  MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription.

Authors:  Sandra Laduron; Rachel Deplus; Sifang Zhou; Olga Kholmanskikh; Danièle Godelaine; Charles De Smet; S Diane Hayward; François Fuks; Thierry Boon; Etienne De Plaen
Journal:  Nucleic Acids Res       Date:  2004-08-17       Impact factor: 16.971

3.  Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Authors:  Valéria C C Andrade; André L Vettore; Roberta S Felix; Manuella S S Almeida; Fabrício Carvalho; José Salvador R Oliveira; Maria Lourdes Lopes Ferrari Chauffaille; Adagmar Andriolo; Otavia L Caballero; Marco Antonio Zago; Gisele W B Colleoni
Journal:  Cancer Immun       Date:  2008-02-01

4.  Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours.

Authors:  A A Jungbluth; E Stockert; Y T Chen; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; K J Busam; L J Old
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

5.  Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate.

Authors:  Ellen C Border; Joseph P Sanderson; Thomas Weissensteiner; Andrew B Gerry; Nicholas J Pumphrey
Journal:  Oncoimmunology       Date:  2018-11-20       Impact factor: 8.110

6.  MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer.

Authors:  S Suzuki; K Sasajima; Y Sato; H Watanabe; T Matsutani; S Iida; M Hosone; T Tsukui; S Maeda; K Shimizu; T Tajiri
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640

7.  Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.

Authors:  Anna Pagotto; Otavia L Caballero; Norbert Volkmar; Sylvie Devalle; Andrew J G Simpson; Xin Lu; John C Christianson
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.